Secondary Logo

Share this article on:

Antibiotic Resistance of Potential Otopathogens Isolated From Nasopharyngeal Flora of Children With Acute Otitis Media Before, During and After Pneumococcal Conjugate Vaccines Implementation

Rybak, Alexis, MD*†; Levy, Corinne, MD*†‡§¶; Bonacorsi, Stéphane, PhD‖**; Béchet, Stéphane, MSc; Vié le Sage, François, MD; Elbez, Annie, MD*††; Varon, Emmanuelle, MD‡‡; Cohen, Robert, MD*†‡§¶§§

The Pediatric Infectious Disease Journal: March 2018 - Volume 37 - Issue 3 - p e72–e78
doi: 10.1097/INF.0000000000001862
Vaccine Reports

Background: To re-evaluate antibiotic strategies for acute otitis media (AOM) in young children, we analyzed the trends of nasopharyngeal carriage and antibiotic resistance of Streptococcus pneumoniae (Sp), Haemophilus influenzae (Hi) and Moraxella catarrhalis (Mc) isolated from young children with AOM during a 16-year period.

Methods: This cross-sectional study analyzed from 2001 to 2016 the nasopharyngeal carriage of Sp, Hi and Mc of young children with AOM. Medical history and physical findings were reported. Periods were defined by pneumococcal conjugate vaccine (PCV) introduction. We separately analyzed the 13-valent PCV (PCV13) period, which started after 2013.

Results: During the study, 12,973 children with AOM were enrolled by 138 pediatricians. By comparing the first and last PCV periods, the proportion of children in day care centers and that of AOM with conjunctivitis significantly increased. The proportion of penicillin nonsusceptible Sp carriage significantly decreased during the study, with 0.8% of penicillin-resistant strains isolated in the PCV13 period, but that of β-lactamase–producing Hi continually increased to 23.6% in 2016. The level of Mc β-lactamase–producing strains remained high (>97%). In the PCV13 period, the main predictors of β-lactamase–producing Hi carriage were conjunctivitis (adjusted odds ratio = 6.0, 95% confidence interval [4.7–7.7]) and attending a day care center (2.4 [1.7–3.5]).

Conclusions: In the PCV13 period, the proportion of penicillin-resistant Sp carriage was very low and that of β-lactamase–producing Hi carriage did not exceed 20% among children with AOM and without conjunctivitis. Our results suggest that amoxicillin may remain the first-line antibiotic treatment for AOM in young children except for those with conjunctivitis, for which amoxicillin-clavulanate is still the best antibiotic.

From the *ACTIV, Association Clinique et Thérapeutique Inflantile du Val-de-Marne, Saint-Maur-des-Fossés, France; AFPA, Association Française de Pédiatrie Ambulatoire, Saint-Germain-en-Laye, France; Université Paris Est, IMRB-GRC GEMINI, Créteil, France; §Clinical Research Center (CRC), Centre Hospitalier Intercommunal de Créteil, Créteil, France; GPIP, Groupe de Pathologie Infectieuse Pédiatrique, Paris, France; Université Paris Diderot, Sorbonne Paris Cité; France; **Service de Microbiologie, Hôpital Robert-Debré, 75019 Paris, France; ††Service de Néonatalogie et Réanimation néonatale, Centre Hospitalier Intercommunal de Créteil, Créteil, France; ‡‡National Reference Center for Pneumococci, Laboratoire de Microbiologie, Assistance Publique-Hôpitaux de Paris, Hopital Européen Georges-Pompidou, Paris, France; and §§Unité Court Séjour, Petits nourrissons, Service de Néonatalogie, Centre Hospitalier Intercommunal de Créteil, France.

Accepted for publication November 28, 2017.

This work was supported by Pfizer Pharmaceuticals France. The sponsor helped design the study but had no role in data collection, data analysis, data interpretation or writing of the report. A.R., C.L. and R.C. had full access to all the data in the study and had final responsibility for the decision to submit for publication. Grants for ACTIV from Pfizer, Novartis, Sanofi and GSK during the conduct of the study. R.C. reports personal fees outside the submitted work from Pfizer, GSK, Sanofi and Novartis. C.L. reports personal fees outside the submitted work from Pfizer and Novartis. F.V.l.S. reports personal fees outside the submitted work from GSK, Sanofi, MSD, Pfizer and Novartis. E.V. received grants from French Institut for Public Health Surveillance during the conduct of the study, grants from Pfizer and personal fees from Pfizer outside the submitted work. The other authors have no conflicts of interest to disclose.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (www.pidj.com).

Address for correspondence: Corinne Levy, MD, ACTIV, 27, rue d’Inkermann, 94100 Saint-Maur-des-Fossés, France. E-mail: corinne.levy@activ-france.fr.

Streptococcus pneumoniae (Sp), Haemophilus influenzae (Hi) and in a lesser extent Moraxella catarrhalis (Mc) are the main bacterial species implicated in acute otitis media (AOM),1–3 the leading reason for antibiotics prescription in childhood.4 , 5 Even if most episodes of AOM resolve spontaneously,6 , 7 in most countries, antibiotics are indicated for AOM in young children to reduce the duration of symptoms and the risk of complications.8 , 9 The choice of antibiotic prescriptions must consider many factors including the bacterial species implicated and their level of resistance to antibiotics but also the tolerability and the potential ecological impact of the different compounds.

The reservoir of bacterial species implicated in AOM is the nasopharynx, and their carriage precedes AOM.10 , 11 Although NP cultures are not useful to individually predict the etiology of AOM,12 , 13 they have been proposed for following the trends of antibiotic susceptibility and the impact of pneumococcal conjugate vaccines (PCVs).14 , 15 The NP carriage of Sp and Hi varies according to several factors such as number of siblings, crowding, day care center (DCC) attendance, respiratory tract infections, and also antibiotics use and vaccine selective pressure.16 Contrary to Sp and Hi, almost all strains of Mc are β-lactamase–producing, with no variability over time.17

Since 1996 in France, amoxicillin-clavulanate (AC) or cefpodoxime-proxetil (third-generation cephalosporin; 3GC) was recommended in official guidelines for treating AOM in young children.18 These choices were mainly supported by the high level of β-lactamase–producing Hi strains (about 40%) in this period.19 After the implementation of PCVs20 , 21 and the plan to reduce antibiotics use for community-acquired infections,22 the proportion of both penicillin-resistant Sp and β-lactamase–producing Hi carriage decreased, which led to change guidelines in 2011.21 For children <2 years old with AOM, the recommended treatment changed to amoxicillin given at 80–90 mg/kg/day21 according to the reduced proportion of β-lactamase–producing Hi strains and the potential for 3GC to increase the carriage and infection by extended-spectrum β-lactamase enterobacteriacae.23 However, for children with AOM and conjunctivitis, according to the role of Hi in this clinical entity, AC remained the recommended compound.21 , 24 Tympanocentesis was only recommended after a second antibiotic treatment failure.21

The dynamics of Sp and Hi antibiotic resistance justifies a sequential re-evaluation to consider changing the treatment strategies in AOM. Hence, 6 years after the change in recommended antibiotics for AOM and 4 years after PCV13 implementation, we aimed to assess this question by analyzing the trends of Sp and Hi antibiotic resistance in NP carriage in France.

Back to Top | Article Outline

MATERIALS AND METHODS

Study Design

Bacteriologic data on NP carriage from 2001 to 2016 were obtained by using a cross-sectional study to monitor Sp NP carriage after PCV7 implementation.19 , 25–27 Children of both sexes, from age 6 to 24 months, with a diagnosis of AOM according to Paradise criteria and with fever and/or otalgia were enrolled by 138 pediatricians in all French metropolitan regions.28 Paradise criteria were used since the beginning of the study regardless of other diagnosis criteria for AOM to maintain the same methodology. Medical history and physical findings for each patient were obtained.

Back to Top | Article Outline

Microbiology Investigations

NP specimens were obtained by using cotton-tipped wire swabs as described.19 , 25–27 Swabs were placed in transport medium and transferred within 48 hours to one of the 2 centralized microbiology laboratories (Robert Debré Hospital or National Centre for Pneumococci at European Georges Pompidou Hospital in Paris, France). Morphology and standard methods were used to identify Sp and Hi strains (Hi and Mc strains were not identified between 2001 and 2005). The agar-dilution method with minimal inhibitory concentration (MIC) was used to determine susceptibility of Sp strains to penicillin. Isolates were divided into penicillin-susceptible (MIC ≤0.06 mg/L), penicillin-intermediate–resistant (MIC 0.06–2.0 mg/L) and penicillin-resistant (MIC >2 mg/L) according European Committee on Antimicrobial Susceptibility Testing breakpoints (Table version 7.1 available at http://www.eucast.org/clinical breakpoints/). Penicillin-nonsusceptible Sp (PNSP) isolates were defined as penicillin-intermediate–resistant and penicillin-resistant strains (MIC >0.06 μg/mL).

Hi and Mc strains were tested for production of β-lactamase by chromogenic cephalosporin test for ampicillin susceptibility. Hi strains were classified as ampicillin-susceptible (MIC ≤1 mg/L) and ampicillin-resistant (MIC >1 mg/L). β-Lactamase–negative, ampicillin-resistance strains were determined according to the Clinical and Laboratory Standards Institute breakpoints by a chromogenic cephalosporin test.29 Hi strains were serotyped by the slide agglutination method with specific antisera.

Back to Top | Article Outline

Statistical Analysis

Data were double entered by using 4D SAS v6.4 to v12.5 (4D SAS, Le Pecq, France) and analyzed by using Stata/SE v13.1 (StataCorp, College Station, TX). We defined 5 periods according to the implementation of PCV7 and PCV13 in France20 , 30 , 31: pre-PCV7 (2001–2002), nongeneralized PCV7 (2003–2005), PCV7 (2006–2010), PCV7 to PCV13 transition (2011–2012) and PCV13 (≥2013). We used multinomial logistic regression for analysis of factors associated with penicillin-susceptible and -nonsusceptible Sp carriage as well as non-β-lactamase–producing and β-lactamase–producing Hi carriage in the PCV13 period. Clinical variables with P < 0.20 (sex, age, day care attendance modalities, siblings, fever and otalgia, otorrhea, conjunctivitis, otitis prone children, history of AOM, bilateral AOM, last antibiotic received in the last 3 months) on univariate analysis were included in the multinomial model, estimating adjusted odds ratios (aORs) and 95% confidence intervals (CIs). Quantitative data were compared by analysis of variance and qualitative data by χ2 test. All tests were 2-sided and considered significant at P < 0.05. Cuzick’s test for trend was performed over the years. Because several studies showed cross-reactive functional antibodies after PCV13 vaccination, we analyzed the vaccine serotypes as PCV13 serotype + 6C.32 , 33 Serotypes 15B and 15C were counted as only one serotype (15B/C).

Back to Top | Article Outline

Ethics

The research was conducted in accordance with the Declaration of Helsinki and national and institutional standards. The study was approved by the Saint-German-en-Laye Ethics Committee. Written informed consent was obtained from parents or legal guardians.

Back to Top | Article Outline

RESULTS

Characteristics of Patients

Among the 12,973 children enrolled by 138 pediatricians, 9.5% (n = 1236), 15.6% (n = 2030), 32.9% (n = 4268), 13.8% (n = 1790) and 28.1% (n = 3649) were included in the pre-PCV7, nongeneralized PCV7, PCV7, transition and PCV13 periods, respectively. Table 1 presents the characteristics of patients according to the 5 periods. During the study, the proportion of children attending a DCC significantly increased from 32.5% to 54.2%. Fever and/or otalgia were less associated with AOM in the PCV13 period, whereas the proportion of AOM with conjunctivitis increased. Antibiotic prescription in the 3 months before enrollment significantly decreased (P < 0.001), with fewer oral 3GC and AC prescriptions and more amoxicillin prescriptions (P < 0.001).

TABLE 1

TABLE 1

Back to Top | Article Outline

Sp, Hi and Mc Carriage

Global Sp carriage slightly but significantly decreased by 18.2% after PCV13 implementation (P < 0.001; Fig. 1 and Table, Supplemental Digital Content 1, http://links.lww.com/INF/C892). The proportion of PCV7 and 6 PCV13 additional vaccine serotypes + 6C greatly decreased by 96.6% (P < 0.001) and 87.2% (P < 0.001), respectively (Fig., Supplemental Digital Content 2, http://links.lww.com/INF/C893). In the PCV13 period, nonvaccine serotypes accounted for 91.7% of Sp strains, and among Sp carriers, the main serotypes were 15B/C (14.1%), 11A (10.4%), 23B (9.3%), 15A (7.0%) and 35B (6.5%).

FIGURE 1

FIGURE 1

During the study period, Hi carriage significantly increased from 46.6 to 57.0% (P < 0.001; Fig. 2). Nontypable Hi represented 99.7% of Hi strains during the whole study.

FIGURE 2

FIGURE 2

Mc carriage slightly decreased between 2006 and 2016 from 53.2% to 49.3% (P = 0.034; Fig., Supplemental Digital Content 3, http://links.lww.com/INF/C894).

Back to Top | Article Outline

Sp Antibiotic Resistance

During the study period, the proportion of PNSP strains significantly decreased by 46.4% (P < 0.001; Fig. 1). In the pre-PCV7 period, 74.4% of these strains were PCV7 vaccine serotypes (Fig. 3). In the PCV7 period, 19A was the most frequent PNSP serotype (41.7%). In the PCV13 period, several different nonvaccine serotypes were PNSP, with 11A accounting for 16.4%, 15A for 16.3%, 35B for 16.1% and 15B/C for 8.5%.

FIGURE 3

FIGURE 3

In the PCV13 period, fully penicillin-resistant strains (MIC >2 μg/mL) accounted for 15 cases (0.8% among Sp carriers and 0.4% among all children); serotype 11A was implicated in 46.7% (n = 7) of cases, with penicillin-MIC between 3 and 8 μg/mL. The other penicillin-resistant serotypes were 9N (n = 1), 15A (n = 1), 15B (n = 1), 19F (n = 2), 29 (n = 1), 35B (n = 1) and nontypable serotype (n = 1).

Back to Top | Article Outline

Hi Antibiotic Resistance

The proportion of Hi β-lactamase–producing strains continually increased after 2012 (11.7%) to reach 23.6% in 2016 (Fig. 2). Furthermore, this proportion was significantly higher in children with than without conjunctivitis during the whole study period (18.4% versus 14.5%, P < 0.001; Fig., Supplemental Digital Content 4, http://links.lww.com/INF/C895). The proportion of β-lactamase–negative, ampicillin-resistance strains remained stable at a low level (<10%) since 2006.

Back to Top | Article Outline

Mc Antibiotic Resistance

The proportion of β-lactamase–producing strains decreased slightly during the study (P < 0.001) but remained >97%.

Back to Top | Article Outline

Risk Factors of PNSP Carriage and β-Lactamase–producing Hi Carriage in the PCV13 Period

On multinomial analysis (Table 2), DCC attendance was associated with carriage of PNSP (aOR = 2.7, 95% CI: 2.1–3.6) and β-lactamase–producing Hi (aOR = 2.4, 95% CI: 1.7–3.5). β-Lactamase–producing Hi carriage was additionally associated with conjunctivitis (aOR = 6.0, 95% CI: 4.7–7.7), siblings (aOR = 1.7, 95% CI: 1.3–2.2), history of AOM (aOR = 1.4, 95% CI: 1.1–1.9) and bilateral AOM (aOR = 1.4, 95% CI, 1.1–1.8).

TABLE 2

TABLE 2

Back to Top | Article Outline

DISCUSSION

Because AOM remains the leading cause of antibiotics prescriptions in children (>70%) after PCVs implementation,4 , 5 the guidelines for antibiotics treatment for this disease could have a major impact on public health. Changes in antibiotic susceptibility could lead to a modification of the guidelines. During the study period, we observed a decrease in the proportion of PNSP strains (reduced by 46.4%) and an opposite trend for β-lactamase–producing Hi strains after 2011, reaching 23.6% in 2016. Moreover, since the beginning of the study, we observed changes in AOM symptomatology, with less severe forms (decreasing rate of patients with otalgia, fever and otorrhea), which may reflect PCVs impact and the decrease of AOM caused by vaccine-type Sp.34

After PCV implementation, in France as in many countries, both pneumococcus carriage rate and the proportion of PNSP strains greatly decreased, mainly because of the decrease of PCV vaccines serotypes.1 , 27 , 35 , 36 Furthermore, in the PCV13 period, the serotypes implicated in the remaining PNSP strains completely changed, with serotypes 11A, 15A, 35B and 15BC accounting for 16.4%, 16.3%, 16.1% and 8.5%, respectively. These serotypes were not frequently isolated in the pre-PCV7 period among the PNSP strains. Moreover, in the PCV13 period, very few penicillin-resistant Sp strains were isolated (0.8%), and the main serotype was 11A. This particular serotype, contrary to serotype 19A which emerged after PCV7 implementation,19 has low AOM37 and invasive disease potential.38 Indeed, these results highlight, one more time, that the appropriate use of antibiotics is a public health priority.

By contrast, for Hi, we report an increase in carriage rate and, in the last 5 years, an increase in proportion of β-lactamase–producing strains. Because Hi carriage was associated with attending a DCC (aOR = 1.9, 95% CI: 1.7–2.2),27 the observed increase in Hi carriage we found could be attributed to the increase in frequency of children attending a DCC (increased by 40%), in accordance with the French national data.39 Concerning the trends of β-lactamase–producing Hi in the last 5 years, the explanations seem more complicated, and several factors could play a role. Among them are the increase in frequency of children attending a DCC and the change in type of antibiotics prescribed. After the antibiotic guidelines published in 2011, the prescriptions of amoxicillin sharply increased and the prescriptions of AC and 3GC greatly decreased.40 Indeed, the use of amoxicillin probably provided an ecologic advantage for β-lactamase–producing Hi. Nonetheless, the main risk factor identified for β-lactamase–producing Hi strains among all children was conjunctivitis (aOR = 6.0, 95% CI: 4.7–7.7).41 During the last 3 years for AOM without conjunctivitis, the percentage of β-lactamase–producing strains remains below 20%.

Mc is the third bacterial species implicated in AOM when using middle-ear fluid culture.2 , 3 In France, although Mc strains are frequently isolated from NP flora, the proportion of AOM because of Mc is very low (<8%).42 However, polymerase chain reaction techniques have increased the proportion of cases in which Mc is found, particularly for children with otorrhea and/or mixed infections or recurrent cases.17 , 43 Although this otopathogen is almost always resistant to amoxicillin through β-lactamase production,17 AOM caused by Mc is described as less severe, extremely rarely complicated (mastoiditis, bacteremia or meningitis) and more likely to resolve spontaneously without antibiotic treatment.2 , 44 For these reasons, many national guidelines (US, UK, Canada, Israel and France) do not consider that M. catarrhalis should be a target for first-line antibiotic treatment in AOM in the same way as Sp and Hi.8 , 9 , 21 , 45 , 46

The main limitation in our study is the use of microbiologic culture of samples from the nasopharynx instead of from middle-ear fluid to analyze resistance of bacterial strains involved in AOM. NP cultures are imperfect to predict individually the etiology of AOM.12 , 13 As shown previously by Kaur et al,14 for epidemiologic studies, NP cultures, when samples are collected at onset of AOM, may predict antibiotic susceptibility of middle-ear fluid. Furthermore, relative change in the prevalence of vaccine-serotype Sp carriage has been described as a predictor of relative change in incidence of AOM because of vaccine-serotypes Sp.15 Indeed, pneumococcus implicated in AOM could differ from those isolated from NP flora. Shouval et al37 addressed the relationship between carriage of individual serotypes and AOM (positive middle-ear fluid culture) and for the serotypes 11A, 15A, 35B and 15B/C did not find any significant positive association. If in some regions, tympanocentesis with culture continue to be performed,47 bacteriologic samples of middle-ear fluid are not routinely obtained in France.48 Indeed, tympanocentesis is mainly used for complicated AOM (unresponsive cases, recurrent cases, otorrhea or with underlying conditions) with probably an overrepresentation of resistant strains.

Sp and Hi NP carriage is a dynamic process mainly subject to antibiotic use, vaccination and interactions between bacterial species in the nasopharyngeal microbiota.16 , 49 , 50 The continuous modification of antibiotic resistance among these 2 otopathogens justifies ongoing NP carriage surveillance and regular update. With this study and the changes observed, the question is the relevance of the treatment strategies in AOM. Although we observed an increase in β-lactamase–producing Hi carriage, amoxicillin should remain the drug of choice for first-line AOM because of its better tolerability and the lesser ecological impact of this compound as compared with AC or 3CG.23

For children with AOM and conjunctivitis, because of the role of Hi and the frequency of β-lactamase–producing Hi carriage, the treatment should remain AC, especially for children attending a DCC.

Back to Top | Article Outline

ACKNOWLEDGMENTS

We thank all pediatricians who participated in the study: C. Abt-Nord, M.-J. Aim-Mille, D. Allain, M. Amzallag, P. André, I. Aubier, P. Bakhache, J. Baron, B. Baszanger, C. Batard, G. Beley, M. Benani, C. Bensoussan-Ambacher, E. Billard, L. Billet, J.-P. Blanc, M.-J. Bodin, E. Boez, B. Bohe, J. Bouglé, F. Bouillot, B. Broussin, J.-L. Cabos, P. Camier, F. Ceccato, A. Chevé, D. Clavel, C. Claverie, R. Cohen, L. Coicadan, F. Corrard, L. Cret, G. d’Acremon, N. D’Ovidio-Panis, B. de Brito, F. De Grenier, P. Deberdt, I. Defives, A. Delatour, J.-F. Delobbe, V. Derkx, V. Desvignes, M. Dogneton, I. Donikian-Pujol, C. Douer-Fernando, M. Dubosc, J. Ducellier, C. Dumont, A. Elbez, J. Elbhar, N. Elkhoury, C. Ferte-Devin, J.-M. Fiorini, D. Garel, J.-L. Gasnier, A. Gasser, B. Gaudin, N. Gelbert-Baudino, P. Gembara, C. Georgeot, M. Gerardin, M. Giorno, M. Goldrey, R. Gorge, J. Gosselin, C. Guiheneuf, J.-L. Guillon, J.-F. Hassan, A. Hayat, H. Hollenberg, P. Huguet, P. Hugot, M. Hunin, A. Kalindjian, K. Kassmann, Z. Klink, M. Koskas, C. Lastman-Lahmi, H. Le Scornet, M.-C. Lemarchand, J.-C. Lévêque, J. Levy, M. Levy, D. Livon, N. Maamri-Belaroussi, C. Magendie, I. Martins, M.-O. Mercier-Oger, C. Messica, F. Meunier, A.-S. Michot, J. Miclot, P. Migault, I. Nave, M. Navel, J.-F. Nicolas, M.-O. Oger, J. Ohayon, J.-C. Oilleau, A. Pappo, F. Paratte, J. Peguet, C. Perrin, C. Petit, B. Pinçant, O. Pinard, A. Piollet, J.-F. Pujol, M.-T. Pujol, N. Ramos, S. Ravilly, Y. Regnard, M. Robert, O. Romain, S. Romano, M.-C. Rondeau, B. Saade, C. Salinier-Rolland, C. Schlemmer, E. Seror, G. Sivelle, D. Somerville, N. Temam-Basse, J.-M. Thiron, F. Thollot, J. Toledanno, R. Touitou, C. Turberg-Romain, J. Vaugeois, F. Vie Le Sage, J.-L. Vuillemin, A. Werner, R. Wisnewsky, A. Wollner, C. Wollner, C. Ythier. We thank M. Boucherat, M. Fernandes, I. Ramay, D. Menguy, C. Prieur, A. Prieur and E. Sobral and N. Hamouda for technical assistance.

Back to Top | Article Outline

REFERENCES

1. Ben-Shimol S, Givon-Lavi N, Leibovitz E, et al. Impact of widespread introduction of pneumococcal conjugate vaccines on pneumococcal and nonpneumococcal otitis media. Clin Infect Dis. 2016;63:611–618.
2. Broides A, Dagan R, Greenberg D, et al. Acute otitis media caused by Moraxella catarrhalis: epidemiologic and clinical characteristics. Clin Infect Dis. 2009;49:1641–1647.
3. Kaur R, Morris M, Pichichero ME. Epidemiology of acute otitis media in the postpneumococcal conjugate vaccine era. Pediatrics. 2017;140(3)
4. Palmu AA, Jokinen J, Nieminen H, et al. Effect of pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3-4 trial. Lancet Infect Dis. 2014;14:205–212.
5. Sellam A, Chahwakilian P, Cohen R, et al. [Impact of guidelines on ambulatory pediatric antibiotic prescriptions]. Arch Pediatr. 2015;22:595–601.
6. Rosenfeld RM, Vertrees JE, Carr J, et al. Clinical efficacy of antimicrobial drugs for acute otitis media: metaanalysis of 5400 children from thirty-three randomized trials. J Pediatr. 1994;124:355–367.
7. Tahtinen PA, Laine MK, Ruohola A. Prognostic factors for treatment failure in acute otitis media. Pediatrics. 2017;140(3)
8. Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media. Pediatrics. 2013;131:e964–e999.
9. Le Saux N, Robinson JL; Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Management of acute otitis media in children six months of age and older. Paediatr Child Health. 2016;21:39–50.
10. Agrawal A, Murphy TF. Haemophilus influenzae infections in the H. influenzae type b conjugate vaccine era. J Clin Microbiol. 2011;49:3728–3732.
11. Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis. 2004;4:144–154.
12. Syrjänen RK, Herva EE, Mäkelä PH, et al. The value of nasopharyngeal culture in predicting the etiology of acute otitis media in children less than two years of age. Pediatr Infect Dis J. 2006;25:1032–1036.
13. Foglé-Hansson M, White P, Hermansson A. Prediction of upper respiratory tract bacteria in acute otitis media. Acta Otolaryngol. 2007;127:927–931.
14. Kaur R, Czup K, Casey JR, et al. Correlation of nasopharyngeal cultures prior to and at onset of acute otitis media with middle ear fluid cultures. BMC Infect Dis. 2014;14:640.
15. Flasche S, Givon-Lavi N, Dagan R. Using pneumococcal carriage data to monitor postvaccination changes in the incidence of pneumococcal otitis media. Am J Epidemiol. 2016;184:652–659.
16. Albrich WC, Monnet DL, Harbarth S. Antibiotic selection pressure and resistance in Streptococcus pneumoniae and Streptococcus pyogenes. Emerg Infect Dis. 2004;10:514–517.
17. Ngo CC, Massa HM, Thornton RB, et al. Predominant bacteria detected from the middle ear fluid of children experiencing otitis media: a systematic review. PLoS One. 2016;11:e0150949.
18. Anonymous. [Les infections ORL]. Méd Mal Infect. 1997;27(4):334–340.
19. Cohen R, Bingen E, Levy C, et al. Nasopharyngeal flora in children with acute otitis media before and after implementation of 7 valent pneumococcal conjugate vaccine in France. BMC Infect Dis. 2012;12:52.
20. Anonymous. [Calendrier vaccinal 2006 et autres avis du Conseil supérieur d’hygiène publique en France relatifs à la vaccination]. Available in French from: http://invs.santepubliquefrance.fr/beh/2006/29_30/beh_29_30_2006.pdf. 2006. Accessed November 20, 2017.
21. Anonymous (SPILF-SFP-GPIP). [Antibiothérapie par voie générale en pratique courante dans les infections respiratoires hautes de l’adulte et l’enfant]. Available in French from http://www.infectiologie.com/UserFiles/File/medias/Recos/2011-infections-respir-hautes-recommandations.pdf. 2011. Accessed November 20, 2017.
22. Dommergues MA, Hentgen V. Decreased paediatric antibiotic consumption in France between 2000 and 2010. Scand J Infect Dis. 2012;44:495–501.
23. Birgy A, Cohen R, Levy C, et al. Community faecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae in French children. BMC Infect Dis. 2012;12:315.
24. Bodor FF. Conjunctivitis-otitis syndrome. Pediatrics. 1982;69:695–698.
25. Cohen R, Levy C, de La Rocque F, et al. Impact of pneumococcal conjugate vaccine and of reduction of antibiotic use on nasopharyngeal carriage of nonsusceptible pneumococci in children with acute otitis media. Pediatr Infect Dis J. 2006;25:1001–1007.
26. Cohen R, Bingen E, Levy C, et al. [Antibiotic resistance of pneumococci and H. influenzae isolated from the nasopharyngeal flora of children with acute otitis media between 2006 and 2010]. Arch Pediatr. 2011;18:926–931.
27. Angoulvant F, Cohen R, Doit C, et al. Trends in antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae isolated from nasopharyngeal flora in children with acute otitis media in France before and after 13 valent pneumococcal conjugate vaccine introduction. BMC Infect Dis. 2015;15:236.
28. Paradise JL. On classifying otitis media as suppurative or nonsuppurative, with a suggested clinical schema. J Pediatr. 1987;111(6 pt 1):948–951.
29. Nørskov-Lauritsen N, Ridderberg W, Erikstrup LT, et al. Evaluation of disk diffusion methods to detect low-level β-lactamase-negative ampicillin-resistant Haemophilus influenzae. APMIS. 2011;119:385–392.
30. Anonymous. [Calendrier des vaccinations et recommandations vaccinales 2011 selon l’avis du Haut Conseil de la santé publique]. Available in French from: http://solidarites-sante.gouv.fr/fichiers/bo/2011/11-04/ste_20110004_0100_0047.pdf. 2011. Accessed November 20, 2017.
31. Martinot A, Cohen R, Denis F, et al. [Annual trends (2008-2011) in early childhood vaccination coverage for the French population: the Vaccinoscopie(®) study]. Arch Pediatr. 2013;20:837–844.
32. Cooper D, Yu X, Sidhu M, et al. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine. 2011;29:7207–7211.
33. Grant LR, O’Brien SE, Burbidge P, et al. Comparative immunogenicity of 7 and 13-valent pneumococcal conjugate vaccines and the development of functional antibodies to cross-reactive serotypes. PLoS One. 2013;8:e74906.
34. Dagan R, Pelton S, Bakaletz L, et al. Prevention of early episodes of otitis media by pneumococcal vaccines might reduce progression to complex disease. Lancet Infect Dis. 2016;16:480–492.
35. Palmu AA, Toropainen M, Kaijalainen T, et al. Direct and indirect effectiveness of the ten-valent pneumococcal conjugate vaccine against carriage in a cluster-randomized trial. Pediatr Infect Dis J. 2017;36:1193–1200.
36. Kaur R, Casey JR, Pichichero ME. Emerging Streptococcus pneumoniae strains colonizing the nasopharynx in children after 13-valent Pneumococcal conjugate vaccination in comparison to the 7-valent era, 2006-2015. Pediatr Infect Dis J. 2016;35:901–906.
37. Shouval DS, Greenberg D, Givon-Lavi N, et al. Site-specific disease potential of individual Streptococcus pneumoniae serotypes in pediatric invasive disease, acute otitis media and acute conjunctivitis. Pediatr Infect Dis J. 2006;25:602–607.
38. del Amo E, Selva L, de Sevilla MF, et al. Estimation of the invasive disease potential of Streptococcus pneumoniae in children by the use of direct capsular typing in clinical specimens. Eur J Clin Microbiol Infect Dis. 2015;34:705–711.
39. Anonymous (Caisse nationale des Allocations familiales). [Résultats du Rapport 2016 de l’Observatoire national de la petite enfance]. Available in French from: https://www.caf.fr/sites/default/files/cnaf/Documents/DCom/Presse/Communiqu%C3%A9s2016/06122016DossierPresse.pdf. 2016. Accessed November 20, 2017.
40. Levy C, Pereira M, Guedj R, et al. Impact of 2011 French guidelines on antibiotic prescription for acute otitis media in infants. Med Mal Infect. 2014;44:102–106.
41. Cohen R, Levy C, Hentgen V, et al. Relationship between clinical signs and symptoms and nasopharyngeal flora in acute otitis media. Clin Microbiol Infect. 2006;12:679–682.
42. Gehanno P, Panajotopoulos A, Barry B, et al. Microbiology of otitis media in the Paris, France, area from 1987 to 1997. Pediatr Infect Dis J. 2001;20:570–573.
43. Marchisio P, Esposito S, Picca M, et al; Milan AOM Study Group. Prospective evaluation of the aetiology of acute otitis media with spontaneous tympanic membrane perforation. Clin Microbiol Infect. 2017;23:486.e1–486.e6.
44. Courter JD, Baker WL, Nowak KS, et al. Increased clinical failures when treating acute otitis media with macrolides: a meta-analysis. Ann Pharmacother. 2010;44:471–478.
45. Anonymous (National Institute for Health and Care Excellence). Otitis media (acute): antimicrobial prescribing. Available from: https://www.nice.org.uk/guidance/gid-apg10001/documents/draft-guideline. 2017. Accessed November 20, 2017.
46. Marom T, Bobrow M, Eviatar E, et al. Adherence to acute otitis media diagnosis and treatment guidelines among Israeli otolaryngologists. Int J Pediatr Otorhinolaryngol. 2017;95:63–68.
47. Dagan R, Leibovitz E, Greenberg D, et al. Mixed pneumococcal-nontypeable Haemophilus influenzae otitis media is a distinct clinical entity with unique epidemiologic characteristics and pneumococcal serotype distribution. J Infect Dis. 2013;208:1152–1160.
48. Levy C, Thollot F, Corrard F, et al. [Acute otitis media in ambulatory practice: epidemiological and clinical characteristics after 7 valent pneumococcal conjugate vaccine (PCV7) implementation]. Arch Pediatr. 2011;18:712–718.
49. de Steenhuijsen Piters WA, Sanders EA, Bogaert D. The role of the local microbial ecosystem in respiratory health and disease. Philos Trans R Soc Lond B Biol Sci. 2015; 370(1675):pii: 20140294.
50. Faden H, Duffy L, Wasielewski R, et al. Relationship between nasopharyngeal colonization and the development of otitis media in children. Tonawanda/Williamsville Pediatrics. J Infect Dis. 1997;175:1440–1445.
Keywords:

acute otitis media; Streptococcus pneumoniae; Haemophilus influenzae; pneumococcal conjugate vaccine; antibiotic resistance

Supplemental Digital Content

Back to Top | Article Outline
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.